Skip to main content
Elsevier
View Cart
openUserAccount

Books in Neuropharmacology

BooksJournals
11-20 of 30 results in All results

Neuropsychopharmacology: A Tribute to Joseph T. Coyle

  • 1st Edition
  • Volume 76
  • June 7, 2016
  • Robert Schwarcz
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 0 9 7 4 5 - 8
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 9 8 2 0 - 2
Neuropsychopharmacology: A Tribute to Joseph T. Coyle is a new volume from Advances in Pharmacology presenting reviews of recent breakthroughs in glutamate pharmacology and a tribute to one of the most influential neuroscientists of our times. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists, and biochemists alike.

Developing Therapeutics for Alzheimer's Disease

  • 1st Edition
  • May 27, 2016
  • Michael S. Wolfe
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 0 2 1 7 3 - 6
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 2 1 6 4 - 4
Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer’s disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area. Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer’s disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer’s disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics.

Pharmacological Mechanisms and the Modulation of Pain

  • 1st Edition
  • Volume 75
  • February 23, 2016
  • James E Barrett
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 0 3 8 8 3 - 3
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 3 9 3 2 - 8
Pharmacological Mechanisms and the Modulation of Pain, the newest volume in the Advances in Pharmacology series, presents the pharmacological mechanisms and the modulation of pain. With a variety of chapters and the best authors in the field, this volume is an essential resource for pharmacologists, immunologists, and biochemists alike.

Drug Design and Discovery in Alzheimer’s Disease

  • 1st Edition
  • June 2, 2015
  • Atta-ur Rahman + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 8 0 3 9 5 9 - 5
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 3 9 6 0 - 1
Drug Design and Discovery in Alzheimer’s Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of β-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery.

The Neuropsychiatric Complications of Stimulant Abuse

  • 1st Edition
  • Volume 120
  • May 26, 2015
  • Pille Taba + 2 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 0 2 9 7 8 - 7
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 3 0 0 3 - 5
This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume concentrates on the neuropsychiatric complications of stimulant abuse.

TRP Channels as Therapeutic Targets

  • 1st Edition
  • March 14, 2015
  • Arpad Szallasi
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 4 2 0 0 2 4 - 1
  • eBook
    9 7 8 - 0 - 1 2 - 4 2 0 0 7 9 - 1
TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use is authored by experts across academia and industry, providing readers with a complete picture of the therapeutic potential and challenges associated with using TRP channels as drug targets. This book offers a unique clinical approach by covering compounds that target TRP channels in pre-clinical and clinical phases, also offering a discussion of TRP channels as biomarkers. An entire section is devoted to the novel and innovative uses of these channels across a variety of diseases, offering strategies that can be used to overcome the adverse effects of first generation TRPV1 antagonists. Intended for all researchers and clinicians working toward the development of successful drugs targeting TRP channels, this book is an essential resource chocked full of the latest clinical data and findings.

The Endocannabinoidome

  • 1st Edition
  • September 18, 2014
  • Vincenzo Di Marzo + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 4 2 0 1 2 6 - 2
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 0 4 2 9 - 6
The Endocannabinoidome: The World of Endocannabinoids and Related Mediators is dedicated to the latest research and studies on endocannabinoids and cannabinoid receptors to illustrate their important role in the discovery of new, endocannabinoid-related, lipid mediators. Written by leading experts across different disciplines, this book focuses on the biochemical and anlayticial aspects of novel lipid signals, their pharmacological activities and their potential utilization for the development of new and effective therapeutic strategies. The first book of its kind, The Endocannabinoidome is a meaningful reference for all those involved in experimental efforts to further the development of this field.

Providing Pharmacological Access to the Brain

  • 1st Edition
  • Volume 21
  • October 22, 2013
  • Thomas R. Flanagan + 3 more
  • English
  • eBook
    9 7 8 - 1 - 4 8 3 2 - 8 8 3 5 - 2
This volume focuses on contemporary approaches for delivering experimental and therapeutic agents into the brain. The contributions provide methodological details that are typically not available in the literature. Subtleties and shortcuts critical to each procedure are included to facilitate their use by both the experienced researcher and novice.

Global Clinical Trials for Alzheimer's Disease

  • 1st Edition
  • August 28, 2013
  • Menghis Bairu + 1 more
  • English
  • eBook
    9 7 8 - 0 - 1 2 - 4 1 1 5 3 0 - 9
Global Clinical Trials for Alzheimer’s Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer’s disease, there is a need to focus on clinical trials in emerging markets and developing countries. This book provides you with a practical approach to recognizing the opportunities and tackling the challenges that are present during the planning and execution of global clinical trials for Alzheimer’s disease.

Novel Psychoactive Substances

  • 1st Edition
  • August 6, 2013
  • Paul I. Dargan + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 4 1 5 8 1 6 - 0
  • eBook
    9 7 8 - 0 - 1 2 - 4 1 5 9 1 1 - 2
Novel Psychoactive Substances: Classification, Pharmacology and Toxicology provides readers with background on the classification, detection, supply and availability of novel psychoactive substances, otherwise known as "legal highs." This book also covers individual classes of novel psychoactive substances that have recently emerged onto the recreational drug scene and provides an overview of the pharmacology of the substance followed by a discussion of the acute and chronic harm or toxicity associated with the substance. Written by international experts in the field, this multi-authored book is a valuable reference for scientists, clinicians, academics, and regulatory and law enforcement professionals.